PeterGRoseMD

Obstetrics & Gynecology • Cleveland, OH

General Gynecology, Gynecologic Oncology

Professor of Obstetrics & Gynecology, Case West Res University

Join to view full profile

Dr. Rose is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Rose's full profile

Already have an account?

Office
9500 Euclid Ave
Cleveland, OH 44195
Phone+1 800-223-2273
Is this information wrong?

Education & Training

University at BuffaloFellowship, Gynecologic Oncology, 1986 - 1988
Ohio State University/Mt Carmel HospitalResidency, Obstetrics and Gynecology, 1983 - 1986
Vanderbilt University Medical CenterResidency, Surgery, 1981 - 1983
Boston University School of MedicineClass of 1981

Certifications & Licensure

OH State Medical License 1983 - 2026
MA State Medical License 1988 - 2013
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2003-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Northern Ohio Live Castle Connolly, 2007-2009
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Join now to see all

Clinical Trials

Etoposide in Treating Patients With Advanced Ovarian or Cervical Cancer Start of enrollment: 1993 Jun 01
Terminated
Phase 2
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Start of enrollment: 1994 Jun 01
Completed
Phase 3
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 1998 May 01
Terminated
Phase 1
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer Start of enrollment: 1999 Mar 01
Completed
Phase 1
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer Start of enrollment: 1999 Sep 01
Completed
Phase 1
Docetaxel in Treating Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Cancer Start of enrollment: 1998 Jun 01
Terminated
Phase 2
Paclitaxel in Treating Patients With Ovarian Stromal Cancer Start of enrollment: 2000 Nov 20
Completed
Phase 2
Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix Start of enrollment: 2001 Dec 01
Terminated
Phase 2
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer Start of enrollment: 2007 Sep 01
Completed
Phase 1
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer Start of enrollment: 2003 Oct 01
Completed
Phase 1
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Start of enrollment: 2005 Jan 01
Completed
Phase 1
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Start of enrollment: 2005 Mar 21
Active, not recruiting
Phase 3
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2008 Sep 01
Completed
Phase 2
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Exercise and Healthy Diet or Standard Care in Patients in Remission From Stage I or Stage II Endometrial Cancer Start of enrollment: 2008 Jul 01
Completed
Not Applicable
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer Start of enrollment: 2007 Dec 01
Completed
Phase 2
Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Dec 13
Completed
Phase 2
Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01
Completed
YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Start of enrollment: 2007 Sep 01
Terminated
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 2
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Jan 19
Active, not recruiting
Not Applicable
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 2
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
Completed
Phase 1
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors Start of enrollment: 2010 Feb 08
Active, not recruiting
Phase 2
Ovarian Cancer Vaccine for Patients in Remission Start of enrollment: 2010 Jul 01
Completed
Phase 2
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Start of enrollment: 2010 Apr 01
Completed
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
Active, not recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer Start of enrollment: 2010 Jun 07
Completed
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Start of enrollment: 2010 Aug 01
Completed
Phase 2
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Start of enrollment: 2011 Jun 06
Completed
Phase 2
Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Start of enrollment: 2010 Nov 01
Completed
Phase 2
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2011 Oct 01
Completed
Phase 2
Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Start of enrollment: 2011 Mar 14
Completed
Phase 1
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer Start of enrollment: 2011 Apr 04
Active, not recruiting
Phase 1
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Mar 21
Completed
Phase 2
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Start of enrollment: 2012 Jun 18
Completed
Phase 3
Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva Start of enrollment: 2012 Jul 02
Active, not recruiting
Phase 2
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer Start of enrollment: 2013 Sep 30
Completed
Phase 1
Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer Start of enrollment: 2014 Feb 14
Terminated
Phase 2
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
Active, not recruiting
Phase 2, Phase 3
Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ Body Surface Area (BSA) > 2.0 Start of enrollment: 2016 Apr 20
Terminated
Phase 2
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol Start of enrollment: 2020 Jan 15
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
Anthony B Costales, Erin K Crane, Laura Chambers, Meng Yao, Danielle Chau, Wendel R Naumann, Robert Debernardo, Stephanie Ricci, Peter G Rose, Chad M Michener> ;Gynecologic Oncology. 2024 Feb 27
Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer.
Simpson, P., Zhang, L., Christian, Q., Uyar, D., Michener, C., Bishop, E., Hopp, E., Rader, J., Rose, P., Mahdi, H., Debernardo, R., Bradley, W.> ;Frontiers in Oncology. 2024 Jan 1
Response of low HER2-expressing ovarian carcinosarcoma to trastuzumab deruxtecan, a case report.
Rose, P.> ;Gynecologic Oncology Reports. 2023 Dec 1
Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series.
Petty, A., Rose, P., Feldman, M., Podzielinski, I., Vargas, R.> ;Gynecologic Oncology Reports. 2023 Dec 1
1 citations
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chem...
Robert W Holloway, Premal Thaker, Alberto A Mendivil, Sarfraz Ahmad, Ahmed N Al-Niaimi, James Barter, Tiffany Beck, Setsuko K Chambers, Robert L Coleman, Sarah M Craft...> ;International Journal of Gynecological Cancer. 2023 Sep 4
Fam-Trastuzumab Deruxtecan in HER2/Neu-Expressing Serous Endometrial Cancer.
Peter G Rose, Johanna A Kelley, Myra Feldman, Kevin Krivanek> ;JCO Precision Oncology. 2023 Aug 1
2 citations
Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.
Hussein Al-Sudani, Ying Ni, Philip Jones, Huseyin Karakilic, Lei Cui, Lisa D S Johnson, Peter G Rose, Alexander Olawaiye, Robert P Edwards, Robert A Uger, Gloria H Y L...> ;NPJ Precision Oncology. 2023 Jul 19
3 citations
LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.
Goutam Dey, Rashmi Bharti, Chad Braley, Ravi Alluri, Emily Esakov, Katie Crean-Tate, Keith McCrae, Amy Joehlin-Price, Peter G Rose, Justin Lathia, Zihua Gong, Ofer Reizes> ;Journal of Ovarian Research. 2023 Jun 27
Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian can...
Erika J Lampert, Peter G Rose, Meng Yao, Robert DeBernardo, Roberto J Vargas, Chad M Michener, Laura M Chambers> ;International Journal of Gynecological Cancer. 2023 Jul 3
4 citations
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors i...
Omali Pitiyarachchi, Michael Friedlander, James J Java, John K Chan, Deborah K Armstrong, Maurie Markman, Thomas J Herzog, Bradley J Monk, Floor Backes, Angeles Alvare...> ;Gynecologic Oncology. 2022 Sep 1
1 citations
Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study.
Phuong L Mai, Austin Miller, Amanda Black, Roni T Falk, John F Boggess, Katherine Tucker, Ashley R Stuckey, Gustavo C Rodriguez, Cheung Wong, Thomas T Amatruda, Kelly ...> ;American Journal of Obstetrics and Gynecology. 2022 Jul 1
Symptoms of Women With High-Risk Early-Stage Ovarian Cancer.
Peter G Rose> ;Obstetrics and Gynecology. 2022 Jun 1
4 citations
Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer.
Julia Chalif, Meng Yao, Morgan Gruner, Michelle Kuznicki, Roberto Vargas, Peter G Rose, Chad Michener, Robert DeBernardo, Laura Chambers> ;Gynecologic Oncology. 2022 Apr 1
2 citations
Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer.
Laura M Chambers, Meng Yao, Molly Morton, Morgan Gruner, Anna Chichura, Anthony B Costales, Max Horowitz, Peter G Rose, Chad M Michener, Robert Debernardo> ;Gynecologic Oncology Reports. 2022 Apr 1
7 citations
Ovarian cancer recurrence: is the definition of platinum sensitivity modified by PARPi, bevacizumab or other intervening treatments? : a clinical perspective.
Peter G Rose> ;Cancer Drug Resistance. 2022 Jan 1
26 citations
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition.
Ying Ni, Ahmed Soliman, Amy Joehlin-Price, Peter G Rose, Anda Vlad, Robert P Edwards, Haider Mahdi> ;NPJ Precision Oncology. 2021 Dec 17
1 citations
Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma.
Laura M. Chambers, Danielle Chau, Meng Yao, Anthony B. Costales, Peter G. Rose, Chad M. Michener, Robert Debernardo, Roberto Vargas> ;Gynecologic Oncology Reports. 2021 Oct 15
Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma.
Mariam AlHilli, Lisa Rybicki, Caitlin Carr, Meng Yao, Sudha Amarnath, Roberto Vargas, Robert Debernardo, Chad M. Michener, Peter G. Rose> ;Gynecologic Oncology. 2021 Oct 1
6 citations
PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Peter G. Rose, Meng Yao, Laura M. Chambers, Haider Mahdi, Robert Debernardo, Chad M. Michener, Miriam AlHilli, Stephanie Ricci, Roberto Vargas> ;Anti-Cancer Drugs. 2021 Nov 1
6 citations
Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers.
Ying Ni, Ahmed Tamer Soliman, Amy Joehlin-Price, Fadi W. Abdul-Karim, Peter G. Rose, Haider Mahdi> ;Immunotherapy. 2021 Aug 23
5 citations
Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma.
Jonathan T. Hunt, Laura M. Chambers, Meng Yao, Amy Joehlin-Price, Robert Debernardo, Peter G. Rose> ;Gynecologic Oncology Reports. 2021 Jul 24
7 citations
Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
Morgan Gruner, Laura M. Chambers, Meng Yao, Anna Chichura, Molly Morton, Anthony B. Costales, Max Horowitz, Peter G. Rose, Robert Debernardo, Chad M. Michener> ;Gynecologic Oncology. 2021 Sep 1
13 citations
Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemothe...
Laura M. Chambers, Julia Chalif, Meng Yao, Anna Chichura, Molly Morton, Morgan Gruner, Anthony B. Costales, Max Horowitz, Danielle B. Chau, Roberto Vargas, Peter G. Ro...> ;Gynecologic Oncology. 2021 May 31
2 citations
Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospecti...
Laura M. Chambers, Meng Yao, Molly Morton, Anna Chichura, Anthony B. Costales, Max Horowitz, Morgan Gruner, Peter G. Rose, Chad M. Michener, Robert Debernardo> ;International Journal of Gynecological Cancer. 2021 May 18
17 citations
Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer.
Laura M. Chambers, Chad M. Michener, Peter G. Rose, Ofer Reizes, Meng Yao, Roberto Vargas> ;Gynecologic Oncology. 2021 Apr 1
Join now to see all

Press Mentions

Researchers Create Tool to Help Predict Survival for Patients with Advanced Stage Recurrent Ovarian CancerMarch 13th, 2019
The Power of Shared Purpose: Transforming Gynecologic Cancer CareMarch 26th, 2024